ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8(+) T Cells

Cancer vaccines aim to induce CTL responses against tumors. Challenges for vaccine design are targeting Ag to dendritic cells (DCs) in vivo, facilitating cross-presentation, and conditioning the microenvironment for Th1 type immune responses. In this study, we report that ISCOM vaccines, which consi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Immunol
Auteurs principaux: Duewell, Peter, Kisser, Ulrich, Heckelsmiller, Klaus, Hoves, Sabine, Stoitzner, Patrizia, Koernig, Sandra, Morelli, Adriana B., Clausen, Björn E., Dauer, Marc, Eigler, Andreas, Anz, David, Bourquin, Carole, Maraskovsky, Eugene, Endres, Stefan, Schnurr, Max
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4285562/
https://ncbi.nlm.nih.gov/pubmed/21613613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1004114
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires